Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albendazole + ivermectin (Centre d'Appui à la lutte contre la Maladie)
- Development stage
- Unknown
- Lead developer
- Fundación Mundo Sano
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Albendazole + ivermectin is a combination therapy consisting of two small molecule anthelmintic agents used for the treatment and prevention of parasitic infections, specifically lymphatic filariasis caused by *Wuchereria bancrofti*. Albendazole works by binding to the beta-tubulin of the parasite, inhibiting microtubule polymerization and disrupting metabolic pathways. Ivermectin acts by binding to glutamate-gated chloride channels, increasing cell membrane permeability to chloride ions and leading to hyperpolarization and paralysis of the parasite. This specific combination was evaluated in a Phase 4 clinical trial conducted by the Centre d'Appui à la lutte contre la Maladie (CNAM) in Mali to assess its impact on infection and transmission in rural endemic villages as part of mass drug administration efforts.
- Other names
- albendazole + ivermectin-Centre d'Appui à la lutte contre la Maladie-lymphatic filariasisalbendazole and ivermectinivermectin + albendazole
02
Targets
GluCl (Glutamate-gated chloride channel)TUBB (Tubulin (alpha and beta subunits))RDL (Insect GABA-gated chloride channel)
Beyond the preview
Go deeper on albendazole + ivermectin (Centre d'Appui à la lutte contre la Maladie).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albendazole + ivermectin (Centre d'Appui à la lutte contre la Maladie).